All In Biotech

Drug Trial Radar · NCT02426775

Carglumic Acid in Methylmalonic Acidemia and Propionic Acidemia

Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness of the Use of Carbaglu® in Patients With Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA)

Last checked: Nov 20, 2026Latest source record: Apr 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

33

Actual

Start

Nov 2015

Primary completion

Mar 19, 2019

Study completion Mar 19, 2019

Sponsor

Lead sponsor
King Abdullah International Medical Research CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 27, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase IIIb (Three b), Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness \& Safety of the use of Carglumic Acid (Carbaglu®) in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA). Carbaglu® clinical experience in Organic Acidemia (OA) is limited to a non-comparative retrospective collection of data from patients who had received Carbaglu® for 1 to 15 days. There is no current evidence supporting the use of carglumic acid for the chronic management of patients with OA. The investigators are proposing a randomized multicentre prospective clinical trial to evaluate long-term effects of the use of Carbaglu® (50mg/kg/day) combined with standard chronic therapy in patients with PA and MMA compared to standard chronic therapy alone.

Conditions

  • Propionic Acidemia
  • Methylmalonic Acidemia

Interventions

  • Carglumic AcidDrug

    Carglumic Acid 50 mg/kg/day (twice daily)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of emergency visits due to hyperammonemia within 24 months periodTime frame: 24 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • King Abdullah Specialist Children Hospital, King Abdulaziz Medical City

    Riyadh, Saudi Arabia

  • King Fahad Medical City

    Riyadh, Saudi Arabia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.